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Abstract
Purpose Although [18F]FDG PET can measure therapy
response sooner and more accurately than morphological
imaging techniques, there is still some debate as to whether
[18F]FDG uptake really reflects changes in the viable cell
fraction. In this study changes in [18F]FDG uptake were
investigated in a lymphoma model at several time-points
after treatment and with different doses of chemotherapy.
Data were analysed in terms of several parameters.
Methods SCID mice were subcutaneously inoculated with
5×106 Daudi cells in the right thigh. One group was not
treated (control group). The other groups received cyclo-
phosphamide 75 mg/kg (low-dose group), 125 mg/kg
(medium-dose group) and 175 mg/kg (high-dose group) on
day 0. Sequential [18F]FDG small-animal PET (µPET) scans
were performed on days 0, 2, 6, 9, 13 and 16 after treatment.
The mean and maximum standardized uptake value
(SUVmean and SUVmax), metabolic tumour volume (Volmetab)
and total lesion glycolysis (TLG) were calculated.
Results A significant decrease in [18F]FDG uptake was
observed on day 2 in the medium-dose and high-dose
groups and on day 6 in the low-dose group, all preceding
morphological changes. SUVmean and SUVmax formed a
plateau from day 6 to day 9, corresponding to the known
influx of inflammatory cells. No obvious plateau was
observed with TLG which was found to be the most
sensitive parameter clearly differentiating the low-dose group
from the medium- and high-dose groups early after therapy.
Conclusion [18F]FDG uptake was able to reflect the dose–
response relationship for cyclophosphamide. TLG was the
best parameter for dose-related response assessment in this
tumour model.
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Introduction
Lymphomas are highly sensitive to treatment with chemo-
therapy and radiotherapy and have substantial long-term
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cure rates. However, there are still a few patients who have
resistant disease and early change of therapy can improve
survival in these patients. On the other hand, long-term
toxicity of the administered treatment is increasingly
recognized, and in patients with chemosensitive disease,
unnecessary treatment should be avoided. For these
reasons, there is a strong need for tailoring the intensity
of treatment to individual patients on the basis of early
response assessment.
Early response assessment is difficult with conventional
radiographic modalities because reduction in morpholog-
ical tumour volume is only a late sign of effective therapy.
Therefore, anatomic imaging modalities are less suitable
for evaluation of early response assessment. Furthermore,
they cannot distinguish between benign fibrotic scarring
and persisting viable tumour tissue [1]. Several clinical
studies have demonstrated the superiority of [18F]FDG
PET imaging for initial staging of lymphoma, manage-
ment of recurrent cancer and monitoring of therapy
response [2–6].
To be a reliable predictor of response, changes in tumour
[18F]FDG uptake should reflect changes in the viable
tumour cell fraction. However, the rapid decrease in tumour
glucose metabolism after effective therapy is only partly
concordant with uptake in viable tumour cells. A flare
phenomenon has been described very early after chemo-
therapy which has been considered to be due to an
increased metabolism of preapoptotic cells trying to repair
DNA and requiring energy for apoptosis initiation [7, 8].
On the other hand chemotherapy and radiotherapy induce
inflammation and [18F]FDG is highly accumulated in
inflammatory cells, leading to an overestimation of the
viable tumour fraction [9, 10]. It has been shown that
corticosteroid administration can suppress the [18F]FDG
uptake caused by the inflammatory influx [11].
In this study we evaluated [18F]FDG uptake after the
administration of different doses of cyclophosphamide to
define a dose–response relationship and to demonstrate
[18F]FDG PET as a reliable tool for evaluating early therapy
response.
Materials and methods
Animal model
Severe combined immune deficient (SCID) mice (C.B-17/
Icr scid/scid) were inoculated with cells of the Daudi B cell
line, a human lymphoma cell line derived from a Burkitt
lymphoma [10]. Mice were bred under germ-free condi-
tions, and at 6 to 8 weeks of age were subcutaneously
inoculated with 5 million Daudi cells in the right thigh. The
developing tumours were measured twice a week using a
calliper. When the developing tumours had reached a
diameter of about 15 mm, the mice were treated with a
single dose of cyclophosphamide (day 0).
Experimental design
The mice were divided into four groups. The first group
was not treated (four mice, control group). The other groups
received cyclophosphamide on day 0 at doses of 75 mg/kg
(low-dose group, five mice), 125 mg/kg (medium-dose
group, five mice) and 175 mg/kg (high-dose group, four
mice). Small-animal PET (µPET) scans were performed on
day 0 (before treatment) and on days 2, 6, 9, 13 and 16 after
the administration of cyclophosphamide. Tumour dimen-
sions were measured at each time-point using a calliper and
tumour volumes (Volcalliper) were calculated using the
equation: Volcalliper (ml) = (π/6) × a × b × c × 10
−3, where
a, b and c represent the three orthogonal dimensions of the
tumour in millimetres.
µPET scanning
After overnight fasting, µPET scanning was performed
using a Concorde Focus µPET scanner (Knoxville, TN).
The mice were sedated with isoflurane anaesthesia, and
body weight and glycaemia were determined. Then 8–
11 MBq [18F]FDG was injected via a tail vein. µPET
imaging was performed 60 min after injection, (10 min per
frame), in a single bed position with the tumour in the
centre of the view. A few minutes before scanning, the
bladder was emptied to reduce reconstruction artefacts.
Parameters and statistical analysis
For each time-point, the mean standardized uptake value
(SUVmean), maximal SUV (SUVmax) and the metabolic
tumour volume (Volmetab) in the different groups were
measured with different absolute thresholds (SUV 1, 1.1,
1.2 and 1.3) and relative thresholds (40% and 50% of
SUVmax) to determine the most reliable threshold for
volume contouring. Alternatively, inhouse software enabled
visual volume contouring (3-D isocontour) [12]. When no
remaining tumour was present on [18F]FDG PET images,
we used SUVmean of a standard region of interest at the
previous location of the tumour. SUVs were automatically
calculated using the formula: SUV = measured activity
concentration in the tumour (Bq/g) × body weight (g) /
injected activity (Bq). To correct for differences in
administered dose (paravenous injections became more
frequent after several injections), all SUV values were
normalized by dividing the SUV of the tumour by the
corresponding SUVmean of a standard region in the liver
[13].
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Corrections for glycaemia could not add any information
and showed a very high variation intra- and interindividually.
This was possibly related to the very sensitive stress system.
In human studies it is common to correct for glycaemia, but in
our experience, correction for glycaemia in mice does not
change the results but only adds more variability [11].
Total lesion glycolysis (TLG) was defined as SUVmean ×
Volmetab. Decreases in TLG were calculated and expressed
as percentage of the baseline scan on day 0: TLG %
decrease = (TLGx − TLG0)/TLG0 ×100%, where TLGx is
the [18F]FDG uptake on day x (also called deltaTLG or
Larson-Ginsberg Index) [14]. The percentage decreases in
SUVmean, SUVmax and Volmetab were calculated in an
analogous way. Means and SEM (standard error of the
mean) were calculated for the different parameters and are
expressed graphically. Two-tailed p values ≤0.05 were
considered statistically significant. Within each treatment
group unpaired Student’s t-tests were performed to evaluate
changes over time. A Bonferroni correction was subse-
quently used and corrected p values are reported as
pcorrected. To compare overall reductions between treatment
groups over time, the areas under the curve (AUC) of the
different [18F]FDG PET parameters were calculated and
tested using an unpaired Student’s t-test.
Results
Clinical effects and measurement by calliper
The global condition of the mice had deteriorated by 2 to
3 days after treatment. In particular, mice that had received
175 mg/kg cyclophosphamide became apathetic and their
fur became dull, while the global condition of mice that had
received 75 mg/kg was generally not affected. The
clinically measured tumour volume (Volcalliper) in the
control group showed a persistent increase during follow-
up, and the mean Volcalliper increased from 0.82 ml (range
0.54–1.27 ml) on day 0 to 2.60 ml (range 1.86–3.85 ml) on
day 16. In treated mice, a reduction in Volcalliper was seen
from day 6 in the mice in the medium-dose and high-dose
groups (p<0.001 and p=0.004, respectively), and from day
9 in the low-dose group (p<0.001). These volume reduc-
tions were found to be significant after Bonferroni correction
with a pcorrected value of 0.01. All clinically detectable tumour
had almost disappeared from day 13 in the medium-dose and
high-dose groups (Fig. 1a). The low-dose group showed
regrowth on day 16 (Fig. 1a).
Thresholds for volume contouring
Different thresholds for adequate delineation of tumour
volumes were evaluated. We used several absolute and
relative thresholds and visually reviewed the corresponding
volumes. Absolute thresholds were not effective for
evaluation of therapy response in our tumour model as
they often underestimated metabolic tumour volume,
leading to negligible tumour volumes while visually
important tumour tissue remained, especially late after
therapy. Moreover, absolute thresholds are influenced by
the effective injected dose and do not take into account
paravenous injections (that occur more frequently after
several scans) and other subject-dependent differences.
Relative thresholds were also ineffective for tumour
delineation as they were highly dependent on the SUVmax,
leading to under- or overestimation of the tumour volume in
different images. The same observation was made for
thresholds that were a multiple of the SUVmean in the liver
(2× or 3× SUVmean of the liver). We therefore decided to
use the visually based 3-D isocontours. This technique gave
visually satisfying results, was very easy to perform and
was highly reproducible with only minor changes of
Volmetab when the final threshold was slightly altered.
Response monitoring with [18F]FDG PET
There was a fast and obvious response in Volmetab and [
18F]
FDG uptake after chemotherapy (Fig. 1b). The mean Volmetab
of the primary tumours of the treated groups (day 0) was
2.8 ml (range 1 ml to −6.2 ml) and of the control group was
2.2 ml (range 1.3 to 3.2 ml). Volmetab progressively increased
in the control group during follow-up. In contrast, Volmetab
decreased from day 6 onwards in all treated groups, with a
faster and more pronounced decrease with increasing
administered dose. This decrease in Volmetab occurred earlier
after treatment and showed less variability between mice
than the decrease in Volcalliper (Fig. 1). In the low-dose group
Volmetab showed an increase after 16 days of treatment.
Concerning SUVmean, control mice showed a marked
fluctuation corresponding to visual changes in central
necrosis (Fig. 3a). On day 2 a decrease was seen in the
medium-dose group (Fig. 2) and in the high-dose group
(−31±4% and −18±4%, respectively; Fig. 3a). On day 6 all
treatment groups showed a decrease in SUVmean (−35±3%,
−58±3% and −42±5% in the low-, medium- and high-dose
groups, respectively) after which a plateau in SUVmean was
seen between day 6 and day 9. The height of this plateau
was dose dependent. The AUC ΔSUVmean in the low-dose
group was significantly lower than in the medium- and
high-dose groups (p=0.002 and p=0.02, respectively). The
AUC ΔSUVmean was not significantly different between
the medium- and high-dose groups. From day 9 SUVmean
decreased further in the medium- and high-dose groups
(−62±8% and −71±12% on day 16, respectively). The low-
dose group on the other hand showed an increase in
SUVmean from day 13 (−10±13% on day 16).
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SUVmax showed a similar progression over time
(Fig. 3b) with a fast decrease seen on day 2 in the
medium-dose group (−42±4%) and in the high-dose group
(−18±7%) and a significant decrease for the low-dose
group on day 6 (−25.6±9%). Again a plateau was observed
from day 6 to day 9, after which the SUVmax in the
medium- and high-dose groups showed a further decrease
(−66±8% and −78±13% respectively) on day 16 while the
low-dose group showed an increase in SUVmax from day 13
with a value of −13±16% on day 16. Overall the different
treatment groups did not show a significantly different
AUC ΔSUVmax which might have been due to the slightly
higher variability of the SUVmax measurement compared to
the SUVmean.
In contrast to SUVmean and SUVmax, TLG showed more
pronounced differences between the control and treated
groups. Moreover, the TLG response was less variable
between the treatment groups (Fig. 4). The control group
showed a gradual increase in TLG and on day 16 TLG was
about four times the reference value. The TLG in the
medium- and high-dose groups showed a significant
decrease 2 days after treatment (−31±3% and −25±2%,
respectively). In the low-dose group TLG showed a signif-
icant decrease on day 6 (−42±7%), which was significantly
less pronounced than in the medium- and high-dose groups on
day 6 (−72±3% and −71±3%, respectively). The high dose
(175 mg/kg) provided no extra benefit over the medium dose
(125 mg/kg). This was confirmed by the AUC ΔTLG which
was significantly lower in the low-dose group than in the
medium- and high-dose groups (p=0.03 and p=0.04,
respectively). From day 6 TLG showed a further decrease
in all treatment groups. TLG showed an increase in the low-
dose group from day 13 to day 16.
Discussion
Several studies have shown that [18F]FDG PET is a useful
technique for evaluating tumour response to chemotherapy,
and that changes in [18F]FDG uptake appear sooner and are
more accurate than changes in morphological tumour
volume [2–4, 15]. However, it remains unclear which
factors play a role in changing glucose metabolism shortly
after chemotherapy and what is the optimal method for
quantification of tumour response [7–10]. We therefore
evaluated [18F]FDG uptake in a lymphoma animal model
after administration of different doses of cyclophosphamide
with the aim of defining the dose–response relationship.
PET scans were analysed and SUVs were used for
quantitative assessment of tumour glucose metabolism.
Standardized protocols for SUV measurement were shown
to be reproducible and highly accurate for evaluating
response to chemotherapy [16–18]. We also evaluated
response to therapy in terms of volumetric changes in the
tumour measured using a calliper, as several studies have
shown a good correlation between calliper measurements
and the tumour volume [19, 20]. This method was easy,
fast, inexpensive and in comparison to CT or MRI does not
require anaesthesia, scan time or image analysis. However,
errors can occur due to variability in tumour shape, skin
thickness and subcutaneous fat layers. In our study relative
changes in calliper measurements were used to express
response to therapy. Therefore, differences in tumour shape,
skin thickness, subcutaneous fat layer and tumour com-
pressibility would not have had a great influence on the
data. Additionally the measurements were always per-
formed by the same person to reduce the interobserver
variability. As a result, the variations in our measurements
were acceptable. Only for the control group and the low-dose
group did the data show more pronounced variability.
Fig. 1 Changes in Volcalliper (tumor volume measured by calliper) (a)
and Volmetab (metabolic volume measured by [
18F]FDG PET) (b)
during follow-up in control mice and mice treated with 75, 125 and
175 mg/kg cyclophosphamide. The data presented are mean (±SEM)
percentage changes in relation to the reference volumes on day 0
before therapy
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However, these fluctuations were also observed for SUVmean
and SUVmax and in the control group this could have been
due to changes in central necrosis. Although variations in the
calliper measurements were minimized in this study, CT and
MRI are known to be more accurate and reliable for the
assessment of morphological changes [21]. However, the
ready availability of morphological imaging tools as well as
the whole-body irradiation from repeated CT measurements,
potentially impacting the results, led to the current protocol.
Furthermore, the longer anaesthesia protocols necessary for
MRI imaging also increase potential drop-outs. In conclu-
sion, the calliper measurement was the most feasible
approach for the current protocol.
Our first goal was to define an optimal way to delineate
metabolic volume and quantify therapy response. Visual
evaluation of different thresholds in our study showed that
neither absolute nor relative thresholds (40% and 50%
SUVmax) were able to adequately identify residual tumour
tissue after chemotherapy, and that every threshold used
should be compared with (and adapted to) the visual
interpretation of the acquired images. These findings
correspond with the findings of Nestle et al. who compared
different techniques for metabolic tumour contour delinea-
tion and found substantially different volumes, especially in
tumours with inhomogeneous uptake [22]. We used two
different methods for the definition of the minimal SUV
threshold (SUVthreshold) previously described in the literature
[22, 23]. These approaches were not applicable in our
tumour model because of important overestimation of
tumour volumes after treatment. Further investigation of
our dataset could reveal an appropriate standardized thresh-
old in our tumour model, but this would probably not be
applicable to image analysis in humans.
Fig. 3 Changes in SUVmean (a) and SUVmax (b) during follow-up in
control mice and mice treated with 75, 125 and 175 mg/kg
cyclophosphamide. The data presented are mean (±SEM) percentage
changes in relation to the reference values on day 0 before therapy
Day 0 Day 2 Day 6 Day 9 Day 13 Day 16
Fig. 2 Follow-up scans (days 0, 2, 6, 9, 13 and 16) in the same mouse treated with 125 mg/kg cyclophosphamide on day 0. The corresponding
values of Volmetab (Volmet), SUVmean/livermean, SUVmax/livermean, TLG/livermean measured in the same mouse are shown for each time-point
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Despite the implementation of standardized approaches,
there were important differences in tumour size and
characteristics between individuals, underlining the need
to use comparative values (percentage reduction) instead of
absolute quantitative parameters. Correction for injection
problems (e.g. paravenous injection after several scans) by
using the liver uptake as a reference was necessary [13].
Correction for glycaemia proved not to be useful in the
current study, since it led to a higher variability in SUVs
without significantly changing the mean values or the
pattern of the curve. Moreover, below a certain level,
elevated glycaemia might not have an effect on [18F]FDG
uptake in inflammatory cells while it may have an effect in
malignant cells, which makes distinguishing different cell
fractions even more complicated [23].
Changes in PET parameters occurred earlier than
changes in clinically measured tumour volume and showed
less inter- and intraobserver variability, and therefore PET
was more suitable for evaluation of response assessment. A
significant decrease in SUVmean was measured as early as
2 days after chemotherapy. This was in contrast to the
“metabolic flare” observed early after therapy in other
studies [7]. We speculate that the tumour cell line we used
is less sensitive to this effect than those used by others,
possibly because of minimized or delayed energy demand
for repair mechanisms. Following the early decrease in
[18F]FDG uptake, we observed a plateau in FDG uptake
between day 6 and day 9. This stabilization results from the
fact that SUVs are not only a result of [18F]FDG uptake by
viable tumour cells, but also of [18F]FDG uptake in
inflammatory mouse cells, which occurs temporarily with
effective therapy [11]. It has been demonstrated that
approximately 30% of total [18F]FDG uptake can be
attributed to nontumoral tissues and that relative uptake in
inflammatory cells can be even higher than in viable
tumour cells [9]. A previous study by our group has shown
that corticosteroids can decrease the contribution of
inflammatory cells to [18F]FDG uptake [11]. The adminis-
tration of cyclophosphamide resulted in a steady reduction
of the viable tumour cell fraction. On day 9 after treatment
a clear increase in the amount of stromal cells (mainly
macrophages) was measured. These results were obtained
in the same animal model (after administration of 125 mg/
kg cyclophosphamide) corresponding to the medium-dose
group of the current study. Therefore the SUVmean plateau
measured between day 6 and day 9 does not reflect
stabilization of the amount of viable tumour cells, but
represents [18F]FDG uptake in both inflammatory and
malignant cells. As a similar plateau was observed in both
the low- and high-dose groups, we can assume that the
same influx of inflammatory cells occurred, and that
the remaining differential effects were solely due to the
different doses of cyclophosphamide.
These results cannot be generalized to immunocompe-
tent animals or humans because immunodeficient mice
have a suppressed T- and B-cell compartment. Despite
these limitations, these mice have a normal macrophage,
granulocyte and T-cell function, and previous studies have
demonstrated the invasion of stromal cells leading to an
inflammatory reaction after treatment [11]. Our hypothesis
is that the effect in immunocompetent mice will be more
dramatic, because of a more sustained inflammatory
response, but the conclusion will be generally the same.
To the best of our knowledge, no immune-competent
lymphoma mouse model had been described at the time
we set up our experiments. The recent introduction of
syngeneic mouse models opens new perspectives in the
study of the interactions between inflammatory cells and
tumour cells in immune-competent animals. These inter-
actions and their effect on [18F]FDG uptake after therapy
are certainly worth studying in the future. However,
metabolic imaging in immune-suppressed animals will
always remain valuable because the current developments
towards new therapies, addressing specific molecular
targets, will continue to require the study of human cell
lines in vivo.
To determine the optimal parameter for therapy re-
sponse, we compared several semiquantitative PET param-
eters in the different treatment groups. SUVmax showed a
similar pattern to normalized SUVmean, although variability
in SUVmax was larger. The major advantage of SUVmax is
its independence from the threshold used for lesion
contouring and its resistance to interobserver variability. A
different pattern was observed with the TLG parameter
which showed a persisting decrease in metabolic volume.
Fig. 4 Changes in TLG during follow-up in control mice and mice
treated with 75, 125 and 175 mg/kg cyclophosphamide. The data
presented are mean (±SEM) percentage changes in TLG in relation to
the reference TLG on day 0 before therapy
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This parameter most clearly distinguished control from
treated mice. Moreover, early after treatment TLG was
already able to differentiate the low-dose group from the
medium- and high-dose group. This suggests that quantifi-
cation of tumour response after therapy is more reliable
using decreases in TLG than decreases in SUVmean or
SUVmax. It has already been reported that decreases in TLG
are more likely to demonstrate relevant changes than
decreases in SUVmax or SUVmean [14]. The plateau of
SUVmean, as well as the decrease in TLG and Volmetab, was
dose-dependent, although no additional effect was seen as a
result of increasing the dose from 125 mg/kg to 175 mg/kg,
suggesting that there is no additional value in administering
cyclophosphamide at doses higher than 125 mg/kg. This
correlates with the finding of Meyn et al. that the proportion
of apoptotic cells reaches a plateau at doses higher than
100 mg/kg [24]. It is remarkable that the observed plateau
for SUVmean and SUVmax was slightly higher in the
175 mg/kg dose group than in the 125 mg/kg dose group.
This could have been a sampling artefact, as it was not
statistically significant (p=0.056), but could also point to a
more complex mechanism that provoked a higher necrotic
cell fraction in comparison to the apoptotic cell fraction
inducing a more pronounced influx of inflammatory cells.
Kaledin et al. emphasize the complexity of the mechanism
of action of cyclophosphamide and its metabolites in
inducing apoptosis and/or necrosis with increasing doses
[25].
The low-dose group showed increasing SUVs, increas-
ing metabolic volume and increasing TLG in late stages
after therapy (day 16) indicating regrowth of the tumour.
This suggests that a dose of 75 mg/kg is not sufficient to
achieve tumour control and that [18F]FDG PET correlates
with tumour relapse.
A change in [18F]FDG tumour uptake of more than
20% SUV has been suggested as a cut-off value that will
reduce measurement errors and take into account sponta-
neous fluctuations in tumour metabolic activity [26]. In
lymphoma the clinical question is not whether there is an
initial response to therapy but whether the response is
sufficient to cure the patient. For example, if there is a
major decrease in [18F]FDG uptake in a certain tumour
part accompanied by a chemoresistant focus, the uptake in
this focus is relevant for the clinician and crucial for
patient outcome. Consequently, the best PET parameter
predicting relapse is the SUVmax of the resistant tumour
clone. However, in most patients with a solid tumour, or
after several relapses, the main aim is not to attain a
disease-free status, but to achieve a response to the
instituted therapy that prolongs survival and keeps the
disease temporarily under control. In this setting, measur-
ing a parameter reflecting the whole tumour volume is
more logical (TLG, SUVmean or Volmetab).
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